These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35417606)

  • 41. Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma.
    Vithayathil M; D'Alessio A; Fulgenzi CAM; Nishida N; Schönlein M; von Felden J; Schulze K; Wege H; Saeed A; Wietharn B; Hildebrand H; Wu L; Ang C; Marron TU; Weinmann A; Galle PR; Bettinger D; Bengsch B; Vogel A; Balcar L; Scheiner B; Lee PC; Huang YH; Amara S; Muzaffar M; Naqash AR; Cammarota A; Zanuso V; Pressiani T; Pinter M; Cortellini A; Kudo M; Rimassa L; Pinato DJ; Sharma R
    Hepatol Int; 2023 Aug; 17(4):904-914. PubMed ID: 37005953
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of therapeutic outcomes of sorafenib and lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular-targeted agent sequential therapy: A propensity score-matched analysis.
    Tomonari T; Sato Y; Tani J; Hirose A; Ogawa C; Morishita A; Tanaka H; Tanaka T; Taniguchi T; Okamoto K; Sogabe M; Miyamoto H; Muguruma N; Uchida K; Masaki T; Takayama T
    Hepatol Res; 2021 Apr; 51(4):472-481. PubMed ID: 33238074
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
    Maesaka K; Sakamori R; Yamada R; Doi A; Tahata Y; Ohkawa K; Oshita M; Miyazaki M; Yakushijin T; Nozaki Y; Matsumoto K; Tanaka S; Kaneko A; Iio S; Nawa T; Yamada Y; Morishita N; Usui T; Hiramatsu N; Doi Y; Sakakibara M; Imanaka K; Yoshida Y; Kodama T; Hikita H; Tatsumi T; Takehara T
    PLoS One; 2023; 18(2):e0281459. PubMed ID: 36749777
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Atezolizumab plus bevacizumab in advanced hepatocellular carcinoma after treatment failure with multikinase inhibitors.
    Haghnejad V; Muller M; Blaise L; Gerolami R; Bouattour M; Assenat E; Manfredi S; Peron JM; Burcheri-Curatolo A; Lopez A; Ressiot E; Nahon P; Bronowicki JP
    Dig Liver Dis; 2023 Jul; 55(7):938-944. PubMed ID: 37019737
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Usefulness of neutrophil-to-lymphocyte ratio in predicting progression and survival outcomes after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
    Ochi H; Kurosaki M; Joko K; Mashiba T; Tamaki N; Tsuchiya K; Marusawa H; Tada T; Nakamura S; Narita R; Uchida Y; Akahane T; Kondo M; Mori N; Takaki S; Tsuji K; Kusakabe A; Furuta K; Kobashi H; Arai H; Nonogi M; Tamada T; Hasebe C; Izumi N
    Hepatol Res; 2023 Jan; 53(1):61-71. PubMed ID: 36070216
    [TBL] [Abstract][Full Text] [Related]  

  • 47. First-Line Systemic Treatment Strategies for Unresectable Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.
    Liu W; Quan B; Lu S; Tang B; Li M; Chen R; Ren Z; Yin X
    Front Oncol; 2021; 11():771045. PubMed ID: 35004289
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative safety and efficacy of molecular-targeted drugs, immune checkpoint inhibitors, hepatic arterial infusion chemotherapy and their combinations in advanced hepatocellular carcinoma: findings from advances in landmark trials.
    Pan Y; Wang R; Hu D; Xie W; Fu Y; Hou J; Xu L; Zhang Y; Chen M; Zhou Z
    Front Biosci (Landmark Ed); 2021 Oct; 26(10):873-881. PubMed ID: 34719212
    [No Abstract]   [Full Text] [Related]  

  • 49. Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience.
    Sinner F; Pinter M; Scheiner B; Ettrich TJ; Sturm N; Gonzalez-Carmona MA; Waidmann O; Finkelmeier F; Himmelsbach V; De Toni EN; Ben Khaled N; Mohr R; Fründt TW; Kütting F; Bömmel FV; Lieb S; Krug S; Bettinger D; Schultheiß M; Jochheim LS; Best J; Müller C; Keitel V; Venerito M
    Cancers (Basel); 2022 Dec; 14(23):. PubMed ID: 36497447
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma.
    Xu YJ; Lai ZC; He MK; Bu XY; Chen HW; Zhou YM; Xu L; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M; Li QJ
    Technol Cancer Res Treat; 2021; 20():15330338211063848. PubMed ID: 34898313
    [No Abstract]   [Full Text] [Related]  

  • 51. Advanced hepatocellular carcinoma treated by transcatheter arterial chemoembolization with drug-eluting beads plus lenvatinib versus sorafenib, a propensity score matching retrospective study.
    Xue M; Wu Y; Zhu B; Zou X; Fan W; Li J
    Am J Cancer Res; 2021; 11(12):6107-6118. PubMed ID: 35018245
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients.
    Mohamed YI; Duda DG; Awiwi MO; Lee SS; Altameemi L; Xiao L; Morris JS; Wolff RA; Elsayes KM; Hatia RI; Qayyum A; Chamseddine SM; Rashid A; Yao JC; Mahvash A; Hassan MM; Amin HM; Kaseb AO
    Oncotarget; 2022 Dec; 13():1314-1321. PubMed ID: 36473155
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pretreatment Modified Albumin-Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma.
    Tanaka T; Takata K; Yokoyama K; Fukuda H; Yamauchi R; Fukunaga A; Shakado S; Sakisaka S; Hirai F
    Curr Oncol; 2022 Jul; 29(7):4799-4810. PubMed ID: 35877241
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy, Safety, and Patient-Reported Outcomes of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Thailand: A Multicenter Prospective Study.
    Charonpongsuntorn C; Tanasanvimon S; Korphaisarn K; Payapwattanawong S; Siripoon T; Pakvisal N; Juengsamarn J; Phaibulvatanapong E; Chindaprasirt J; Prasongsook N; Udomdamrongkul K; Ngamphaiboon N; Sirachainan E
    JCO Glob Oncol; 2022 Nov; 8():e2200205. PubMed ID: 36455172
    [TBL] [Abstract][Full Text] [Related]  

  • 55. First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
    Chiang CL; Chan SK; Lee SF; Choi HC
    Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33668100
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Real-World Lenvatinib
    Kuo YH; Lu SN; Chen YY; Kee KM; Yen YH; Hung CH; Hu TH; Chen CH; Wang JH
    Front Oncol; 2021; 11():737767. PubMed ID: 34760699
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial.
    Salem R; Li D; Sommer N; Hernandez S; Verret W; Ding B; Lencioni R
    Cancer Med; 2021 Aug; 10(16):5437-5447. PubMed ID: 34189869
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study.
    Huang X; Xu L; Ma T; Yin X; Huang Z; Ran Y; Ni Y; Bi X; Che X
    Front Oncol; 2021; 11():751159. PubMed ID: 34868952
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
    Eso Y; Takeda H; Taura K; Takai A; Takahashi K; Seno H
    Curr Oncol; 2021 Oct; 28(5):4157-4166. PubMed ID: 34677270
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.
    Agirrezabal I; Brennan VK; Colaone F; Shergill S; Pereira H; Chatellier G; Vilgrain V
    Adv Ther; 2022 May; 39(5):2035-2051. PubMed ID: 35279814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.